Nigeria Set to Receive Breakthrough HIV Prevention Injection Lenacapavir in March — NACA!
Reported by Mustapha Labake Omowumi (journalist)| Sele Media Africa
The Nigeria is expected to take delivery of the long-acting HIV prevention drug Lenacapavir in March 2026, according to the National Agency for the Control of AIDS (NACA), in what health authorities describe as a potentially transformative step in the country’s fight against new infections.
NACA officials say the injectable pre-exposure prophylaxis (PrEP) medication administered twice yearly has demonstrated exceptionally strong effectiveness in late-stage clinical trials, offering new hope for populations at high risk of HIV exposure.
A Potential Game-Changer in HIV Prevention
Lenacapavir, developed by Gilead Sciences, is part of a new generation of long-acting HIV prevention tools designed to overcome adherence challenges associated with daily oral PrEP.
Clinical trial data released in 2024 indicated near-complete protection among participants when the drug was used as prescribed. Public health experts caution, however, that real-world effectiveness will depend on rollout quality, accessibility, and sustained funding.
Health authorities in Nigeria say preparations are underway to integrate the injectable into existing HIV prevention programmes, particularly targeting key and vulnerable populations.
Nigeria’s HIV Burden and Strategic Response
Nigeria carries one of the largest HIV burdens globally, with millions of people living with the virus. The introduction of long-acting PrEP options aligns with the country’s broader strategy to reduce new infections and meet global elimination targets.
According to NACA, the planned March 2026 arrival of Lenacapavir forms part of a coordinated effort involving federal health agencies, international partners, and donor organisations.
The World Health Organization and UNAIDS have both highlighted long-acting prevention technologies as critical tools in accelerating progress toward ending AIDS as a public health threat.
Access, Equity and Implementation Questions
While public health advocates have welcomed the development, experts stress that affordability, regulatory approvals, and distribution logistics will determine the drug’s impact across Africa.
Stakeholders are also calling for strong community engagement and clear eligibility guidelines to ensure equitable access once the medication becomes available.
If successfully deployed at scale, Lenacapavir could significantly strengthen Nigeria’s HIV prevention arsenal and contribute to broader continental gains against the epidemic.
Sources
Reuters
BBC News
The Guardian
Statements and data from the National Agency for the Control of AIDS (NACA)
Reports from Gilead Sciences, WHO, and UNAIDS
Mustapha Labake Omowumi is a journalist from Ibadan, Oyo State, and a graduate of the Nigeria Certificate in Education (NCE) in Economics and Mathematics. He demonstrates a strong commitment to professional journalism, with a keen interest in writing and storytelling, guided by principles of self-discipline, accuracy, and trustworthiness.
About The Author
Share this:
Discover more from Sele Media Africa
Subscribe to get the latest posts sent to your email.
